US Patent 8221786 Pharmaceutical formulations containing an SGLT2 inhibitor
Patent 8221786 was granted and assigned to Bristol-Myers Squibb on July, 2012 by the United States Patent and Trademark Office.
All edits
Edits on 29 Nov, 2023
Golden AI
Edits made to:
Article (+190 characters)
Article
Patent abstract
Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate
Edits on 21 Sep, 2023
Golden AI
Edits made to:
Infobox (+8 properties)
Infobox
Patent Inventor Names
Dilbir S. Bindra0
Jatin M. Patel0
Li Tao0
Mandar V. Dali0
Nipa Vatsaraj0
Prakash V. Parab0
Ravindra W. Tejwani0
Yongmei Wu0
Edits on 31 May, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08221786 Pharmaceutical formulations containing an SGLT2 inhibitor US Patent 8221786 Pharmaceutical formulations containing an SGLT2 inhibitor
Infobox
Patent Number
082217860
Patent Number
82217860
Edits on 28 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
082217860
Date of Patent
July 17, 2012
0Patent Application Number
129494730
Date Filed
November 18, 2010
0Patent Primary Examiner
Edits on 14 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08221786 Pharmaceutical formulations containing an SGLT2 inhibitor
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08221786
Date of patent
July 17, 2012
Patent application number
12949473
Date Filed
November 18, 2010
Patent primary examiner
Find more entities like US Patent 8221786 Pharmaceutical formulations containing an SGLT2 inhibitor
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
